Dll4-Fc, an inhibitor of Dll4-Notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-κB activity

Molecular Cancer Therapeutics

Volumn 11, Issue 12, 2012, Pages 2578-2587

  Kuramoto, Takuya ^a   Goto, Hisatsugu ^a   Mitsuhashi, Atsushi ^a   Tabata, Sho ^a   Ogawa, Hirohisa ^a   Uehara, Hisanori ^a   Saijo, Atsuro ^a   Kakiuchi, Soji ^a   Maekawa, Yoichi ^a   Yasutomo, Koji ^a   Hanibuchi, Masaki ^a   Akiyama, Shin Ichi ^a   Sone, Saburo ^a   Nishioka, Yasuhiko ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DELTA LIKE 4 NOTCH SIGNALING; DLL4 FC; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOTCH RECEPTOR; PROTEIN; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; LIVER METASTASIS; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL MOVEMENT; DOWN-REGULATION; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MALE; MICE; MICE, SCID; NF-KAPPA B; RECEPTORS, NOTCH; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871395780     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0640     Document Type: Article

References (40)

1. Minna JD, Kurie JM, Jacks T. A big step in the study of small cell lung cancer. Cancer Cell 2003;4:163-6. (Pubitemid 37163829)
2. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6. (Pubitemid 29291335)
3. Westhoff B, Colaluca IN, D'Ario G, Donzelli M, Tosoni D, Volorio S, et al. Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A 2009;106:22293-8.
4. Weng AP, Ferrando AA, Lee W, Morris JP IV, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71. (Pubitemid 39336870)
5. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7. (Pubitemid 41330622)
6. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7. (Pubitemid 46018516)
7. Hellström M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445:776-80. (Pubitemid 46279716)
8. Benedito R, Roca C, Sörensen I, Adams S, Gossler A, Fruttiger M, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009;137:1124-35.
9. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, et al. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Nat Cell Biol 2011;13:1202-13.
10. Yamanda S, Ebihara S, Asada M, Okazaki T, Niu K, Ebihara T, et al. Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade. Blood 2009;113:3631-9.
11. Stewart KS, Zhou Z, Zweidler-McKay P, Kleinerman ES. Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. Blood 2011;117:719-26.
12. Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, et al. Delta-like ligand 4-notch blockade and tumor radiation response. J Natl Cancer Inst 2011;103:1778-98.
13. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther 2000;7:1063-6. (Pubitemid 30398356)
14. Maekawa Y, Minato Y, Ishifune C, Kurihara T, Kitamura A, Kojima H, et al. Notch2 integrates signaling by the transcription factors RBP-J and CREB1 to promote T cell cytotoxicity. Nat Immunol 2008;9:1140-7.
15. Maekawa Y, Tsukumo S, Chiba S, Hirai H, Hayashi Y, Okada H, et al. Delta1-Notch3 interactions bias the functional differentiation of activated CD4+ T cells. Immunity 2003;19:549-59. (Pubitemid 37311436)
16. Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res 2000;12:209-17.
17. Yano S, Nishioka Y, Izumi K, Tsuruo T, Tanaka T, Miyasaka M, et al. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int J Cancer 1996;67:211-7. (Pubitemid 26274152)
18. Ogino H, Hanibuchi M, Kakiuchi S, Trung VT, Goto H, Ikuta K, et al. E7080 suppresses hematogenous multiple organ metastases of lung cancer cells with nonmutated epidermal growth factor receptor. Mol Cancer Ther 2011;10:1218-28.
19. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-87.
20. Inohara N, Koseki T, del Peso L, Hu Y, Yee C, Chen S, et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem 1999;274:14560-7.
21. Gabr AG, Goto H, Hanibuchi M, Ogawa H, Kuramoto T, Suzuki M, et al. Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression. Clin Exp Metastasis 2012;29:207-16.
22. Hou B, Eren M, Painter CA, Covington JW, Dixon JD, Schoenhard JA, et al. Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. J Biol Chem 2004;279:18127-36. (Pubitemid 38623225)
23. Helbig G, ChristophersonKWII, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, et al. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631-8. (Pubitemid 36792563)
24. Tulchinsky E, Prokhortchouk E, Georgiev G, Lukanidin E. A kappaB-related binding site is an integral part of the mts1 gene composite enhancer element located in the first intron of the gene. J Biol Chem 1997;272:4828-35. (Pubitemid 27090029)
25. Vincenti MP, Coon CI, Brinckerhoff CE. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum 1998;41:1987-94. (Pubitemid 28506689)
26. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-77.
27. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007;67:11244-53. (Pubitemid 350248550)
28. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo . Cancer Res 2011;71:6073-83.
29. Zhang P, Yang Y, Zweidler-McKay PA, Hughes DP. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res 2008;14:2962-9.
30. Sonoshita M, Aoki M, Fuwa H, Aoki K, Hosogi H, Sakai Y, et al. Suppression of Colon Cancer Metastasis by Aes through Inhibition of Notch Signaling. Cancer Cell 2011;19:125-37.
31. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002;2:664-74. (Pubitemid 37328724)
32. Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest 2008;88:11-7.
33. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Downregulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006;66:2778-84.
34. Shin HM, Minter LM, Cho OH, Gottipati S, Fauq AH, Golde TE, et al. Notch1 augments NF-kappaB activity by facilitating its nuclear retention. EMBO J 2006;25:129-38. (Pubitemid 43077302)
35. Oswald F, Liptay S, Adler G, Schmid RM. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 1998;18:2077-88. (Pubitemid 28152657)
36. Schwarzer R, Dörken B, Jundt F. Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012;26:806-13.
37. Sourbier C, Danilin S, Lindner V, Steger J, Rothhut S, Meyer N, et al. Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 2007;67:11668-76.
38. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-speci fic metastasis. Nat Rev Immunol 2011;11:597-606.
39. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003;167:1676-86. (Pubitemid 36760683)
40. Kakiuchi S, Daigo Y, Tsunoda T, Yano S, Sone S, Nakamura Y. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003;1:485-99. (Pubitemid 36577045)